2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimates
2008
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
Cady B, Nathan N, Michaelson J, Golshan M, Smith B. Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site. Annals Of Surgical Oncology 2008, 15: 3384-3395. PMID: 18726129, DOI: 10.1245/s10434-008-0085-x.Peer-Reviewed Original ResearchConceptsPrimary site surgeryBreast cancer patientsMatched-pair analysisIV patientsCancer resectionBreast surgeryCancer patientsSurvival advantageStage IVSite surgeryStage IV breast cancer patientsStage IV breast cancerExcellent responseApparent survival benefitBreast cancer resectionPrimary cancer resectionStage IV patientsStage III patientsSelection biasApparent survival advantageMatched pair analysisOligo metastasisInitial chemotherapyChart reviewSurvival benefit